DK1297825T3 - Faste orale dosisformer af simethicon - Google Patents

Faste orale dosisformer af simethicon

Info

Publication number
DK1297825T3
DK1297825T3 DK02256741T DK02256741T DK1297825T3 DK 1297825 T3 DK1297825 T3 DK 1297825T3 DK 02256741 T DK02256741 T DK 02256741T DK 02256741 T DK02256741 T DK 02256741T DK 1297825 T3 DK1297825 T3 DK 1297825T3
Authority
DK
Denmark
Prior art keywords
simethicone
dosage forms
oral dosage
solid oral
solid
Prior art date
Application number
DK02256741T
Other languages
Danish (da)
English (en)
Inventor
Christopher E Szymczak
James T Walter
Original Assignee
Mcneil Ppc Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mcneil Ppc Inc filed Critical Mcneil Ppc Inc
Application granted granted Critical
Publication of DK1297825T3 publication Critical patent/DK1297825T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK02256741T 2001-09-28 2002-09-27 Faste orale dosisformer af simethicon DK1297825T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/966,441 US7101573B2 (en) 2001-09-28 2001-09-28 Simethicone solid oral dosage form
EP02256741A EP1297825B1 (en) 2001-09-28 2002-09-27 Simethicone solid oral dosage form

Publications (1)

Publication Number Publication Date
DK1297825T3 true DK1297825T3 (da) 2005-09-26

Family

ID=25511414

Family Applications (1)

Application Number Title Priority Date Filing Date
DK02256741T DK1297825T3 (da) 2001-09-28 2002-09-27 Faste orale dosisformer af simethicon

Country Status (18)

Country Link
US (3) US7101573B2 (cg-RX-API-DMAC7.html)
EP (1) EP1297825B1 (cg-RX-API-DMAC7.html)
AR (1) AR036700A1 (cg-RX-API-DMAC7.html)
AT (1) ATE296619T1 (cg-RX-API-DMAC7.html)
AU (1) AU2002301259C1 (cg-RX-API-DMAC7.html)
BR (1) BR0204001A (cg-RX-API-DMAC7.html)
CA (1) CA2405190C (cg-RX-API-DMAC7.html)
CO (1) CO5390073A1 (cg-RX-API-DMAC7.html)
DE (1) DE60204403T2 (cg-RX-API-DMAC7.html)
DK (1) DK1297825T3 (cg-RX-API-DMAC7.html)
ES (1) ES2243664T3 (cg-RX-API-DMAC7.html)
HU (1) HUP0203176A2 (cg-RX-API-DMAC7.html)
MX (1) MXPA02009570A (cg-RX-API-DMAC7.html)
NZ (1) NZ521657A (cg-RX-API-DMAC7.html)
PL (1) PL204141B1 (cg-RX-API-DMAC7.html)
PT (1) PT1297825E (cg-RX-API-DMAC7.html)
RU (1) RU2362569C2 (cg-RX-API-DMAC7.html)
ZA (1) ZA200207755B (cg-RX-API-DMAC7.html)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6632429B1 (en) 1999-12-17 2003-10-14 Joan M. Fallon Methods for treating pervasive development disorders
US7985420B2 (en) * 2000-04-28 2011-07-26 Reckitt Benckiser Inc. Sustained release of guaifenesin combination drugs
US8012504B2 (en) * 2000-04-28 2011-09-06 Reckitt Benckiser Inc. Sustained release of guaifenesin combination drugs
US6955821B2 (en) 2000-04-28 2005-10-18 Adams Laboratories, Inc. Sustained release formulations of guaifenesin and additional drug ingredients
US7838032B2 (en) * 2000-04-28 2010-11-23 Reckitt Benckiser Inc. Sustained release of guaifenesin
US20070053895A1 (en) 2000-08-14 2007-03-08 Fallon Joan M Method of treating and diagnosing parkinsons disease and related dysautonomic disorders
US8030002B2 (en) * 2000-11-16 2011-10-04 Curemark Llc Methods for diagnosing pervasive development disorders, dysautonomia and other neurological conditions
US7101573B2 (en) * 2001-09-28 2006-09-05 Mcneil-Pcc, Inc. Simethicone solid oral dosage form
US7179488B2 (en) 2001-11-29 2007-02-20 Bob Sherwood Process for co-spray drying liquid herbal extracts with dry silicified MCC
AU2002219964A1 (en) * 2001-11-29 2003-06-17 Penwest Pharmaceutical Company Agglomerated particles including an active agent coprocessed with silicified microcrystalline cellulose
SE0200895D0 (sv) * 2002-03-22 2002-03-22 Astrazeneca Ab New pharmaceutical composition
US7341742B2 (en) * 2002-09-30 2008-03-11 L. Perrigo Company Simethicone containing tablet composition and method
EP1563837A1 (en) * 2004-02-03 2005-08-17 Ferrer Internacional, S.A. Hypocholesterolemic compositions comprising a statin and an antiflatulent agent
BRPI0509861A (pt) * 2004-04-13 2007-10-16 Boehringer Ingelheim Int uso de simeticona em pacientes constipados
US20080255104A1 (en) * 2004-05-04 2008-10-16 Equitech Corporation Nsaid Compositions
US20060024409A1 (en) * 2004-07-29 2006-02-02 Everett Laboratories, Inc. Compositions and methods for nutrition supplementation
US20060024384A1 (en) * 2004-07-29 2006-02-02 Giordano John A Compositions and methods for nutrition supplementation
US20060198838A1 (en) * 2004-09-28 2006-09-07 Fallon Joan M Combination enzyme for cystic fibrosis
WO2006100875A1 (ja) * 2005-03-24 2006-09-28 Daiichi Sankyo Company, Limited 医薬用組成物
US20080058282A1 (en) * 2005-08-30 2008-03-06 Fallon Joan M Use of lactulose in the treatment of autism
BRPI0615607A2 (pt) * 2005-08-30 2011-05-24 Lek Pharmaceuticals composição farmacêutica compreendendo perindopril ou seus sais
KR101252635B1 (ko) * 2006-04-20 2013-04-10 (주)아모레퍼시픽 리파아제 저해제 및 친유성 오일흡수제를 포함하는 약학조성물 및 이로부터 제조된 경구 투여용 제제
US20080015260A1 (en) * 2006-07-13 2008-01-17 Kiel Laboratories, Inc. Pharmaceutical compositions having improved stability and methods for preparation and use
US20080038410A1 (en) * 2006-08-18 2008-02-14 Everett Laboratories, Inc. Compositions and methods for nutrition supplementation
EP2086543A2 (en) 2006-10-27 2009-08-12 The Curators of the University of Missouri Compositions comprising at least one acid labile proton pump inhibiting agents, optionally other pharmaceutically active agents and methods of using same
WO2008056200A1 (en) * 2006-11-10 2008-05-15 Ranbaxy Laboratories Limited Oral pharmaceutical compositions of simethicone
MX2009005339A (es) 2006-11-21 2009-06-01 Mcneil Ppc Inc Suspensiones analgesicas de liberacion modificada.
US9833510B2 (en) * 2007-06-12 2017-12-05 Johnson & Johnson Consumer Inc. Modified release solid or semi-solid dosage forms
US20090004248A1 (en) * 2007-06-29 2009-01-01 Frank Bunick Dual portion dosage lozenge form
WO2009105568A1 (en) 2008-02-20 2009-08-27 The Curators Of The University Of Missouri Composition comprising a combination of omeprazole and lansoprazole, and a buffering agent, and methods of using same
US8658163B2 (en) 2008-03-13 2014-02-25 Curemark Llc Compositions and use thereof for treating symptoms of preeclampsia
US8084025B2 (en) 2008-04-18 2011-12-27 Curemark Llc Method for the treatment of the symptoms of drug and alcohol addiction
US9320780B2 (en) 2008-06-26 2016-04-26 Curemark Llc Methods and compositions for the treatment of symptoms of Williams Syndrome
US11016104B2 (en) 2008-07-01 2021-05-25 Curemark, Llc Methods and compositions for the treatment of symptoms of neurological and mental health disorders
US10776453B2 (en) 2008-08-04 2020-09-15 Galenagen, Llc Systems and methods employing remote data gathering and monitoring for diagnosing, staging, and treatment of Parkinsons disease, movement and neurological disorders, and chronic pain
US20100092447A1 (en) 2008-10-03 2010-04-15 Fallon Joan M Methods and compositions for the treatment of symptoms of prion diseases
GB2480772B (en) 2009-01-06 2013-10-16 Curelon Llc Compositions and methods for the treatment or prevention of staphylococcus aureus infections and for the eradication or reduction of staphylococcus aureus
CN105031628B (zh) 2009-01-06 2020-10-02 加尔纳根有限责任公司 治疗或预防大肠杆菌导致的经口感染的组合物和方法
US20100247586A1 (en) * 2009-03-27 2010-09-30 Andreas Hugerth Multi-Portion Intra-Oral Dosage Form With Organoleptic Properties
JP5410819B2 (ja) * 2009-04-09 2014-02-05 ライオン株式会社 木クレオソート含有固形製剤
US9056050B2 (en) 2009-04-13 2015-06-16 Curemark Llc Enzyme delivery systems and methods of preparation and use
US9511125B2 (en) 2009-10-21 2016-12-06 Curemark Llc Methods and compositions for the treatment of influenza
GB2503852B (en) 2011-04-21 2018-12-12 Curemark Llc Compounds for the treatment of neuropsychiatric disorders
WO2012170676A1 (en) 2011-06-08 2012-12-13 Sti Pharma, Llc Controlled absorption water-soluble pharmaceutically active organic compound formulation for once-daily administration
SG2014012132A (en) * 2011-09-08 2014-06-27 Novartis Ag Use of an aromatase inhibitor for the treatment of hypogonadism and related diseases
JP6240610B2 (ja) * 2011-10-27 2017-11-29 サリックス ファーマシューティカルズ,インコーポレイテッド 電解質下剤
ITMI20112221A1 (it) * 2011-12-05 2013-06-06 Altergon Sa Formulazioni stabili in capsule di gelatina molle di antiaggreganti piastrinici, acidi grassi omega-3 e amilosio
CA2858821A1 (en) 2011-12-14 2013-06-27 Disphar International B.V. Simethicone formulation
RU2491941C1 (ru) * 2011-12-27 2013-09-10 Вадим Алексеевич Козловский Композиционный энтеросорбент
US10350278B2 (en) 2012-05-30 2019-07-16 Curemark, Llc Methods of treating Celiac disease
GB201506755D0 (en) 2015-04-21 2015-06-03 Reckitt Benckiser Llc Novel pharmaceutical formulation
MA41620A (fr) 2015-05-14 2018-01-09 Abdi Ibrahim Ilac Sanayi Ve Ticaret A S Composition pharmaceutique comprenant de la siméthicone et de l'otilonium
JP6724537B2 (ja) * 2015-05-26 2020-07-15 大正製薬株式会社 固形製剤
US10166185B2 (en) * 2015-06-09 2019-01-01 J. Rettenmaier & Söhne Gmbh + Co Kg Excipient and oral solid dosage forms for oily drugs
WO2016201119A1 (en) * 2015-06-09 2016-12-15 J. Rettenmaier & Söhne Gmbh + Co Kg Excipient and oral solid dosage forms for oily drugs
EP3294269A1 (en) 2015-06-12 2018-03-21 Santa Farma Ilaç Sanayi A.S. Oral pharmaceutical composition comprising otilonium bromide and simethicone with certain bulk density and improved dissolution characteristics
EP3364955B1 (en) 2015-10-09 2022-04-20 RB Health (US) LLC Pharmaceutical formulation
MX385008B (es) * 2016-12-14 2025-03-14 Rhein Siegfried Sa De Cv Composicion mejorada de lansoprazol y simeticona y procesos para prepararla.
US12226464B2 (en) 2017-04-10 2025-02-18 Curemark, Llc Compositions for treating addiction
WO2019064112A1 (en) 2017-09-29 2019-04-04 Johnson & Johnson Consumer Inc. SOLID PARTICLES OF SIMETHICONE AND THEIR DOSAGE FORM
US11541009B2 (en) 2020-09-10 2023-01-03 Curemark, Llc Methods of prophylaxis of coronavirus infection and treatment of coronaviruses
FR3117780B1 (fr) * 2020-12-22 2024-04-05 Oreal Composition anhydre sous forme de poudre compacte comprenant un sel de magnesium et de la cellulose microcristalline
CN116159032A (zh) * 2023-03-31 2023-05-26 成都恒瑞制药有限公司 盐酸西替利嗪片及其制备方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS56169622A (en) * 1980-06-03 1981-12-26 Kissei Pharmaceut Co Ltd Method of making solid preparation from oily substance
US4744987A (en) * 1985-03-08 1988-05-17 Fmc Corporation Coprocessed microcrystalline cellulose and calcium carbonate composition and its preparation
US4851226A (en) * 1987-11-16 1989-07-25 Mcneil Consumer Products Company Chewable medicament tablet containing means for taste masking
US4906478A (en) * 1988-12-12 1990-03-06 Valentine Enterprises, Inc. Simethicone/calcium silicate composition
US5073384A (en) * 1989-10-19 1991-12-17 Valentine Enterprises, Inc. Maltodextrin/defoaming composition combinate
US5275822A (en) * 1989-10-19 1994-01-04 Valentine Enterprises, Inc. Defoaming composition
NZ235876A (en) * 1989-11-01 1992-06-25 Mcneil Ppc Inc Pharmaceutical compositions containing effective amount of antidiarrheal composition and antiflatulent effective amount of simethicone
US5075114A (en) * 1990-05-23 1991-12-24 Mcneil-Ppc, Inc. Taste masking and sustained release coatings for pharmaceuticals
CA2068402C (en) * 1991-06-14 1998-09-22 Michael R. Hoy Taste mask coatings for preparation of chewable pharmaceutical tablets
JP3177707B2 (ja) 1991-10-08 2001-06-18 堀井薬品工業株式会社 消化管内ガス除去剤
NZ252433A (en) * 1992-04-30 1996-07-26 Schering Corp Preparation of a dry hydrated cephalosporin powder formulation which is resistant to air oxidation and dehydration by mixing the drug with dry excipients and filling into a sealable storage container
GR1002332B (el) * 1992-05-21 1996-05-16 Mcneil-Ppc Inc. Νεες φαρμακευτικες συνθεσεις που περιεχουν σιμεθεικονη.
CA2110313C (en) * 1992-12-01 2004-10-26 Edward John Roche Pharmaceutical compositions containing a guanidinothiazole compound and antacids
FR2705966B1 (fr) * 1993-06-04 1995-08-25 Dow Corning Sa Compositions antimousse utiles notamment pour le traitement de troubles gastriques.
EP0725630A1 (en) * 1993-10-28 1996-08-14 The Procter & Gamble Company Fast dissolving dosage forms containing magnesium aluminum silicate and multiple active ingredients
EP0659403B1 (en) 1993-12-15 2001-03-14 National Starch and Chemical Investment Holding Corporation Use of oil adsorbent natural polymer for cosmetic and pharmaceutical applications
IL139728A (en) * 1995-01-09 2003-06-24 Penwest Pharmaceuticals Compan Aqueous slurry composition containing microcrystalline cellulose for preparing a pharmaceutical excipient
US5585115A (en) * 1995-01-09 1996-12-17 Edward H. Mendell Co., Inc. Pharmaceutical excipient having improved compressability
US6106865A (en) * 1995-01-09 2000-08-22 Edward Mendell Co., Inc. Pharmaceutical excipient having improved compressibility
US6103260A (en) * 1997-07-17 2000-08-15 Mcneil-Ppc, Inc. Simethicone/anhydrous calcium phosphate compositions
US6190696B1 (en) * 1998-06-08 2001-02-20 Pieter J. Groenewoud Stabilized thyroxine medications
US6126967A (en) 1998-09-03 2000-10-03 Ascent Pediatrics Extended release acetaminophen particles
US7101573B2 (en) * 2001-09-28 2006-09-05 Mcneil-Pcc, Inc. Simethicone solid oral dosage form

Also Published As

Publication number Publication date
EP1297825B1 (en) 2005-06-01
HUP0203176A2 (hu) 2004-07-28
CA2405190C (en) 2010-11-09
RU2362569C2 (ru) 2009-07-27
US20100135982A1 (en) 2010-06-03
PT1297825E (pt) 2005-08-31
AU2002301259C1 (en) 2009-07-23
CA2405190A1 (en) 2003-03-28
DE60204403T2 (de) 2006-05-04
DE60204403D1 (de) 2005-07-07
US7101573B2 (en) 2006-09-05
AU2002301259B2 (en) 2009-01-22
HU0203176D0 (cg-RX-API-DMAC7.html) 2002-11-28
BR0204001A (pt) 2003-09-16
RU2002125821A (ru) 2004-03-27
ES2243664T3 (es) 2005-12-01
AR036700A1 (es) 2004-09-29
US7691409B2 (en) 2010-04-06
US20030091624A1 (en) 2003-05-15
PL204141B1 (pl) 2009-12-31
CO5390073A1 (es) 2004-04-30
ATE296619T1 (de) 2005-06-15
US20070196468A1 (en) 2007-08-23
NZ521657A (en) 2004-05-28
MXPA02009570A (es) 2004-07-30
PL356358A1 (en) 2003-04-07
EP1297825A1 (en) 2003-04-02
ZA200207755B (en) 2004-03-26

Similar Documents

Publication Publication Date Title
DK1297825T3 (da) Faste orale dosisformer af simethicon
ATE289796T1 (de) Orale zusammensetzung
DK1417180T3 (da) Fremstilling af aminopyrimidinforbindelser
DK1674084T3 (da) Forlænget frigivelse af oral dosissammensætning
DE60223654D1 (de) Resistzusammensetzung
DK1448235T3 (da) Orale, farmaceutiske sammensætninger af 5,8,14-triaza-tetracyclo[10.3.1.0(2,11).0(4.9)]-hexadeca-2(11),3,5,7,9-pentaen med kontrolleret frigivelse
DK1438306T3 (da) Derivater af UK-2A
ATE353627T1 (de) Stabilisierte orale suspensionsformulierung
DE60143178D1 (de) Lichtempfindliche Zusammensetzung
ATE537831T1 (de) Orale aripiprazol-lösung
NO20040125L (no) Enterale formuleringer
FI20011478L (fi) Farmaseuttinen koostumus
EE05020B1 (et) Glburiidi ravimkoostis
DE10196204T1 (de) Orale Vorrichtungen
IS7051A (is) Lyfjasamsetningar
DE60203537D1 (de) 5ht1-rezeptoragonist enthaltendes arzneimittel
NO20034556D0 (no) Imidazotriazinon-holdige sammensetninger for nasal administrering
DE60326998D1 (de) Orale zubereitung
NO20041968L (no) Anvendelse av cystationin
EP1445096A4 (en) IMPACT-RESISTANT FILM
NO20040857L (no) Ny oral forlenget frigivelses doseringsform.
NO20040966L (no) Orale vaksiner.
FI20011778A0 (fi) Ryhmälähetyksen toteutus
EE200300434A (et) Farmatseutiliselt toimivate ühendite kasutamine
DE60223828D1 (de) Spermizide